- Previous Close
2.2900 - Open
2.2900 - Bid --
- Ask --
- Day's Range
2.2400 - 2.3500 - 52 Week Range
0.9500 - 4.1600 - Volume
1,366,370 - Avg. Volume
1,537,333 - Market Cap (intraday)
769.994M - Beta (5Y Monthly) 1.38
- PE Ratio (TTM)
-- - EPS (TTM)
-2.2200 - Earnings Date Oct 31, 2024 - Nov 4, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
6.75
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.
www.nuvationbio.comRecent News: NUVB
View More
Performance Overview: NUVB
Trailing total returns as of 10/1/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NUVB
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NUVB
View MoreValuation Measures
Market Cap
769.99M
Enterprise Value
207.51M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
361.31
Price/Book (mrq)
2.99
Enterprise Value/Revenue
144.60
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-54.37%
Return on Equity (ttm)
-88.30%
Revenue (ttm)
1.44M
Net Income Avi to Common (ttm)
-510.72M
Diluted EPS (ttm)
-2.2200
Balance Sheet and Cash Flow
Total Cash (mrq)
577.17M
Total Debt/Equity (mrq)
2.76%
Levered Free Cash Flow (ttm)
-290.49M
Research Analysis: NUVB
View MoreCompany Insights: NUVB
NUVB does not have Company Insights
Research Reports: NUVB
View MoreDaily – Vickers Top Buyers & Sellers for 04/11/2022
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 12/20/2021
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 12/13/2021
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 11/03/2021
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.